Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients

Item

http://www.wikidata.org/entity/Q36091962

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Effectiveness and risk factors ...... erienced HIV-infected patients

@ast

Effectiveness and risk factors ...... erienced HIV-infected patients

@en

type

Item

label

Effectiveness and risk factors ...... erienced HIV-infected patients

@ast

Effectiveness and risk factors ...... erienced HIV-infected patients

@en

prefLabel

Effectiveness and risk factors ...... erienced HIV-infected patients

@ast

Effectiveness and risk factors ...... erienced HIV-infected patients

@en

P1476

Effectiveness and risk factors ...... erienced HIV-infected patients

@en

P2093

Alfredo Francisco Villagómez-Ruíz

http://www.w3.org/2001/XMLSchema#string

Bulmaro Manjarrez-Tellez

http://www.w3.org/2001/XMLSchema#string

Gloria Huerta-García

http://www.w3.org/2001/XMLSchema#string

Ivan Martínez-Abarca

http://www.w3.org/2001/XMLSchema#string

Javier Enrique Cruz-Herrera

http://www.w3.org/2001/XMLSchema#string

Jesús Gaytán-Martínez

http://www.w3.org/2001/XMLSchema#string

Jorge Luis Sandoval-Ramírez

http://www.w3.org/2001/XMLSchema#string

Juan Carlos Domínguez-Hermosillo

http://www.w3.org/2001/XMLSchema#string

Marcelino Chavez-García

http://www.w3.org/2001/XMLSchema#string

Marco Isaac Banda-Lara

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.

Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals.

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.

Virologic and immunologic effectiveness at 48 weeks of darunavir-ritonavir-based regimens in treatment-experienced persons living with HIV-1 infection in clinical practice: a multicenter Brazilian cohort.

Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.

High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil.

Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).

P2888

s12981-015-0072-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12981-015-0072-9

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

José Antonio Mata-Marín

P577

2015-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282199218

http://www.w3.org/2001/XMLSchema#string

P6179

1044810467

http://www.w3.org/2001/XMLSchema#string

P698

26413132

http://www.w3.org/2001/XMLSchema#string

P921

virology

P932

4582634

http://www.w3.org/2001/XMLSchema#string